Skip to main content

Table 3 Estimated hazard ratios for treatment effect (active treatment versus placebo) and associated 95% confidence intervals, by frailty index

From: No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over

  Stroke Cardiovascular events Total mortality
Frailty index HR 95% CI HR 95% CI HR 95% CI
0.1 0.75 0.40–1.38 0.62 0.42–0.92 0.89 0.63–1.25
0.2 0.66 0.43–1.01 0.60 0.45–0.78 0.84 0.66–1.07
0.3 0.59 0.36–0.96 0.57 0.42–0.79 0.80 0.61–1.04
0.4 0.52 0.25–1.09 0.55 0.34–0.89 0.76 0.50–1.14
0.5 0.47 0.16–1.33 0.53 0.26–1.06 0.72 0.40–1.29
0.6 0.41 0.10–1.65 0.50 0.20–1.27 0.68 0.32–1.48
  1. All models adjusted by age, sex, and interaction between treatment and frailty index, and stratified by region of recruitment.